Scholar Rock Heading To Finish Line In SMA With Positive Pivotal Data
Executive Summary
Phase III success positions Scholar Rock’s selective myostatin inhibitor for regulatory filings in early 2025. Analysts see a blockbuster opportunity for additive therapy in spinal muscular atrophy.